Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021
Vericel Corporation (NASDAQ:VCEL) will host a webcast and conference call on August 4, 2021, at 8:30 AM EDT to discuss its second-quarter 2021 financial results. Investors can join the call via telephone or through the company’s website. The presentation slides will also be available online. Vericel is known for its advanced therapies in sports medicine and severe burn care, marketing products like MACI® and Epicel®. The call will be accessible for replay until August 11, 2021. For further details, visit the Vericel investor relations page.
- Host of a conference call to discuss financial results, demonstrating transparency.
- Continued focus on advanced therapies in sports medicine and severe burn care.
- None.
CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2021 financial results and business highlights.
| What: | Vericel Corporation Second-Quarter 2021 Earnings Call |
| When: | Wednesday, August 4, 2021 at 8:30am (EDT) |
| Where: | http://investors.vcel.com/events-presentations |
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events-presentations. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. Presentation slides for the conference call will be available on the webcast and in the Investor Relations section of the Vericel website. |
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation second-quarter 2021 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until August, 2022. A replay of the call will also be available until 11:30am (EDT) on August 11, 2021 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 5824035.
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.
Investor Contacts:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
What date will Vericel Corporation announce its Q2 2021 financial results?
How can I participate in the Vericel Corporation earnings call?
What products does Vericel Corporation offer?
Is there a replay available for the Vericel earnings call?
What is the ticker symbol for Vericel Corporation?
